Cover Image
市場調查報告書

α1抗胰蛋白酶製劑的全球市場 (2016∼2020年)

Global Alpha-1 Antitrypsin Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 357352
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
α1抗胰蛋白酶製劑的全球市場 (2016∼2020年) Global Alpha-1 Antitrypsin Drugs Market 2016-2020
出版日期: 2016年04月27日 內容資訊: 英文 58 Pages
簡介

α1抗胰蛋白酶,是稱為A1PI (α1蛋白分解酵素抑制劑)的肝臟生成的糖蛋白質之一,促進彈性蛋白酶等酵素的非活性化,外傷發炎時進行防止蛋白質破損的工作。血液中的α1抗胰蛋白酶水平下降時稱作α1抗胰蛋白酶缺損症 (AATD) 的難治之症,更進一步導致呼吸系統、肝臟疾病和重度皮膚感染疾病。該疾病原因是從父母給孩子的遺傳缺損遺傳基因。透過從人類血漿抽出的藥物的擴大療法,能維持血液中的α1抗胰蛋白酶的濃度,緩和症狀。全球α1抗胰蛋白酶製劑市場2016∼2020年關於,35.42%年複合成長率 (CAGR) 預計成長。

本報告提供全球α1抗胰蛋白酶製劑市場相關分析,包含疾病概要和主要的診斷、治療方法 (開發中產品資訊),市場概要、結構,市場規模趨勢 (今後5年的預測值),各給藥途徑、各地區的詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 α1抗胰蛋白酶缺損症:概要

  • 病理生理學
  • 症狀
  • 診斷
  • 管理

第6章 α1抗胰蛋白酶製劑:概要

  • 血漿的結構要素
  • 血漿來歷的治療藥相關法規
  • 監督機構
  • 醫療費償付

第7章 開發中產品分析

  • D1-AAT
  • B1-AAT
  • C1-AAT
  • rAAV1-CB-hAAT
  • G1-AAT
  • L1-AAT
  • ARC-AAT
  • AAT
  • PTB-101 SDFα
  • ALN-AAT

第8章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第9章 各給藥途徑的市場區隔

  • 非口服式
  • 吸入式

第10章 地區區分

  • 全球α1抗胰蛋白酶製劑市場:各地區的詳細趨勢 (今後6年份)
  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第11章 推動市場要素

  • α1抗胰蛋白酶缺損症 (AATD) 的診斷手法的改良
  • 景氣復甦
  • 新產品的市場機會
  • 未滿足需求高

第12章 推動因素的影響力

第13章 市場課題

  • 嚴格的法規
  • 血漿分餾能力的限制
  • α1抗胰蛋白酶的供不應求
  • 藥物成本高

第14章 推動因素、課題的影響力

第15章 市場趨勢

  • 策略性的產業聯盟與M&A (企業合併、收購)
  • 專利支援計劃
  • 治療方法的認識度的上升

第16章 供應商環境

  • 競爭方案
  • 市場佔有率分析
  • Baxter International
  • CSL Behring
  • Grifols
  • Kamada
  • 其他卓越供應商

第17章 附錄

  • 簡稱集

第18章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR8456

About Alpha-1 antitrypsin Drugs

Alpha-1 antitrypsin, also known as an alpha-1 protease inhibitor (A1PI), is a glycoprotein produced in the liver that helps in the inactivation of enzymes such as elastase, which break down proteins during inflammation induced by some injury. The decline in alpha-1 antitrypsin levels in the blood results in a rare genetic condition known as alpha-1 antitrypsin deficiency (AATD), which leads to the development of respiratory and liver diseases, and severe skin infections. The disease is passed on from parents to an offspring through mutated genes. Augmentation therapy using drugs derived from human plasma helps in maintaining levels of alpha-1 antitrypsin in the blood, helping in remission of the condition.

Technavio's analysts forecast the global alpha-1 antitrypsin drugs market to grow at a CAGR of 35.42% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global alpha-1 antitrypsin drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded drugs and off-label drugs used for the symptomatic treatment of diseases occurring due to alpha-1 antitrypsin deficiency and other disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Alpha-1 Antitrypsin Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Baxter International
  • CSL Behring
  • Grifols
  • Kamada

Other Prominent Vendors

  • Abeona Therapeutics
  • Alnylam Pharmaceuticals
  • Applied Genetic Technologies
  • Arrowhead Research
  • Baxalta
  • Biogen
  • Chiesi
  • Curaxys
  • Laboratoire francais du Fractionnement et des Biotechnologies
  • ProBioGen
  • ProMetic Life Sciences

Market driver

  • Improved diagnosis of alpha-1 antitrypsin deficiency (AATD)
  • For a full, detailed list, view our report

Market challenge

  • Limited plasma fractionation capacity
  • For a full, detailed list, view our report

Market trend

  • Increasing awareness about therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Alpha-1 antitrypsin deficiency

  • Pathophysiology
  • Symptoms
  • Diagnosis
  • Management

PART 06: Overview: Alpha-1 antitrypsin drugs

  • Components of blood plasma
  • Regulation of plasma therapeutics
  • Regulatory authorities
  • Reimbursement

PART 07: Pipeline analysis

  • D1-AAT
  • B1-AAT
  • C1-AAT
  • rAAV1-CB-hAAT
  • G1-AAT
  • L1-AAT
  • ARC-AAT
  • AAT
  • PTB-101 SDF Alpha
  • ALN-AAT

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by route of administration

  • Parenteral
  • Inhalation

PART 10: Geographical segmentation

  • Global alpha-1 antitrypsin drugs market by geography 2015-2020
  • Alpha-1 antitrypsin drugs market in Americas
  • Alpha-1 antitrypsin drugs market in EMEA
  • Alpha-1 antitrypsin drugs market in APAC

PART 11: Market drivers

  • Improved diagnosis of AATD
  • Improving economic conditions
  • Novel product opportunities
  • High unmet needs

PART 12: Impact of drivers

PART 13: Market challenges

  • Stringent regulations
  • Limited plasma fractionation capacity
  • Shortage of alpha-1 antitrypsin supply
  • High cost of drugs

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Strategic alliances and M&A
  • Patient assistance programs
  • Increasing awareness about therapy

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Baxter International
  • CSL Behring
  • Grifols
  • Kamada
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Common symptoms of AATD
  • Exhibit 03: Blood plasma composition
  • Exhibit 04: Plasma proteins composition by percentage share
  • Exhibit 05: Process of derivation of alpha-1 antitrypsin from plasma
  • Exhibit 06: Regulatory policies of plasma proteins therapeutics
  • Exhibit 07: Global alpha-1 antitrypsin drugs market: Products in pipeline
  • Exhibit 08: Global alpha-1 antitrypsin drugs market 2015-2020 ($ billions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global alpha-1 antitrypsin drugs market by geography 2015
  • Exhibit 11: Global alpha-1 antitrypsin drugs market by geography 2015-2020 ($ millions)
  • Exhibit 12: Alpha-1 antitrypsin drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 13: Alpha-1 antitrypsin drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 14: Alpha-1 antitrypsin drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 15: Global alpha-1 antitrypsin drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 16: Impact of drivers
  • Exhibit 17: Impact of drivers and challenges
  • Exhibit 18: Global alpha-1 antitrypsin drugs market share analysis 2015
  • Exhibit 19: Baxter International: Business segmentation by revenue 2014
  • Exhibit 20: Baxter International: YoY growth rate and revenue of BioScience segment 2012-2014 ($ billions)
  • Exhibit 21: Baxter International: YoY growth rate and revenue of Glassia in the US, Canada, Australia and New Zealand 2012-2014 ($ millions)
  • Exhibit 22: Baxter International: Key takeaways
  • Exhibit 23: CSL Behring: Sales by area of therapy 2014
  • Exhibit 24: CSL Behring: Key takeaways
  • Exhibit 25: Grifols: YoY growth rate and revenue of bioscience segment 2012-2014 ($ billions)
  • Exhibit 26: Grifols: Key takeaways
  • Exhibit 27: Kamada: Business segmentation by revenue 2014
  • Exhibit 28: Kamada: YoY growth rate and revenue of Glassia (excluding US, Canada, Australia, and New Zealand) 2012-2014 ($ millions)
  • Exhibit 29: Kamada: Key takeaways
Back to Top